Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.

In a pre-specified superiority analysis at the 10-week time-point, the reduction in mortality risk in the AmBisome group compared with the control group did not reach statistical significance in the unadjusted analyses (risk difference -3.9%; 95% CI, -10.0% to 2.2%;), but was statistically significant in adjusted analysis (risk difference - 5.7%; 95% CI, -11.4% to -0.04%) when adjusting for co-variates associated with cryptococcal mortality.

also in 111,027 other papers